 BEVERLY HILLS, Calif., Aug. 13, 2021 PRNewswire -- GT Biopharma, Inc. GT Biopharma or the Company NASDAQ: GTBP, a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary natural killer NK cell engager TriKE protein biologic technology platform, today provided a general business update of events in the second quarter ending June 30, 2021. 